Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

@article{Chang2005PhaseIS,
  title={Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme},
  author={Susan M. Chang and Patrick Yung Chih Wen and Timothy F. Cloughesy and Harry S. Greenberg and David Schiff and Charles A. Conrad and Karen L. Fink and Hillary Robins and Lisa De Angelis and Jeffrey K Raizer and Kenneth R. Hess and Kenneth D. Aldape and Kathleen R. Lamborn and John G. Kuhn and Janet E. Dancey and Michael D. Prados},
  journal={Investigational New Drugs},
  year={2005},
  volume={23},
  pages={357-361}
}
Purpose: Loss of PTEN, which is common in glioblastoma multiforme (GBM), results in activation of the mammalian target of rapapmycin (mTOR), thereby increasing mRNA translation of a number of key proteins required for cell-cycle progression. CCI-779 is an inhibitor of mTOR. The primary objectives of this study were to determine the efficacy of CCI-779 in patients with recurrent GBM and to further assess the toxicity of the drug. Experimental Design: CCI-779 was administered weekly at a dose of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 123 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Similar Papers

Loading similar papers…